Intec Pharma Ltd. (NASDAQ:NTEC) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intec Pharma Ltd.||7||0.00||N/A||-1.32||0.00|
|BioSpecifics Technologies Corp.||64||13.14||N/A||2.73||24.24|
Table 1 demonstrates Intec Pharma Ltd. and BioSpecifics Technologies Corp.’s top-line revenue, earnings per share and valuation.
Table 2 provides Intec Pharma Ltd. and BioSpecifics Technologies Corp.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Intec Pharma Ltd.||0.00%||0%||0%|
|BioSpecifics Technologies Corp.||0.00%||0%||0%|
Ratings and Recommendations for Intec Pharma Ltd. and BioSpecifics Technologies Corp. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Intec Pharma Ltd.||0||0||0||0.00|
|BioSpecifics Technologies Corp.||0||0||1||3.00|
On the other hand, BioSpecifics Technologies Corp.’s potential upside is 38.64% and its consensus price target is $85.
Insider and Institutional Ownership
The shares of both Intec Pharma Ltd. and BioSpecifics Technologies Corp. are owned by institutional investors at 40.23% and 63.5% respectively. Insiders owned roughly 16.08% of Intec Pharma Ltd.’s shares. Insiders Competitively, owned 0.1% of BioSpecifics Technologies Corp. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Intec Pharma Ltd.||-12.87%||-16.85%||-33.83%||-10.36%||6.67%||-29.97%|
|BioSpecifics Technologies Corp.||-3.75%||-1.43%||-2.63%||14.13%||59.21%||9.16%|
For the past year Intec Pharma Ltd. had bearish trend while BioSpecifics Technologies Corp. had bullish trend.
BioSpecifics Technologies Corp. beats on 7 of the 7 factors Intec Pharma Ltd.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.